Zevra Therapeutics Shares Sink After Receiving Regulatory Blow

Dow Jones

07/24

Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder.

The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date.

Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol.

Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request.

"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe," Chief Executive Neil McFarlane said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

July 24, 2026 09:10 ET (13:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2653708790"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653708790\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653708790?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653708790","market":"hk","top_or_hot":-1,"title":"Zevra Therapeutics Shares Sink After Receiving Regulatory Blow","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ZVRA\">Zevra Therapeutics</a> tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n</p>\n<p>\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n</p>\n<p>\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n</p>\n<p>\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n</p>\n<p>\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2026 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zevra Therapeutics Shares Sink After Receiving Regulatory Blow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZevra Therapeutics Shares Sink After Receiving Regulatory Blow\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-24 21:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ZVRA\">Zevra Therapeutics</a> tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n</p>\n<p>\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n</p>\n<p>\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n</p>\n<p>\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n</p>\n<p>\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2026 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653708790","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653708790","pubTimestamp":1784898600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder.The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date.Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol.Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request.\"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said.Write to Connor Hart at connor.hart@wsj.com Dow Jones Newswires","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ZVRA":"Zevra Therapeutics"},"translate_title":"Zevra Therapeutics 股价在受到监管打击后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1.5},"content_text":"Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n\n\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n\n\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n\n\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n\n\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 24, 2026 09:10 ET (13:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}